HYPOXIC PRECONDITIONING AS A KEY ENHANCER OF ANGIOGENESIS: A NOVEL IN VITRO STRATEGY UTILIZING HUCB-MSC SECRETOME AND DAPAGLIFLOZIN TO OPTIMIZE ENDOTHELIAL PROGENITOR CELL FUNCTION IN STABLE CORONARY ARTERY DISEASE

Clicks: 11
ID: 331009
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #308 of 330 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 330 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background and Aims Novel treatment for coronary artery disease(CAD) using angiogenesis approach requires an optimal microenvironment. The human umbilical cord blood mesenchymal stem cells secretome (hUCB-MSCs) contains paracrine factors that promote new vessel formation, while hypoxic preconditioning enhances endothelial progenitor cell(EPC) responsiveness. This study evaluates hypoxia preconditioning to optimize the secretome and dapagliflozin combination in inducing angiogenesis in vitro. Methods EPCs were isolated from stable CAD patients and cultured under normoxic or 48-hour hypoxic conditions. Each group was further stratified into control, 20% secretome, and secretome with 50 μM dapagliflozin combination group. Angiogenesis was assessed by tube formation assay using ImageJ software and functional analysis by measurement of endothelial nitric oxide synthase (eNOS) and von Willebrand factor (VWF) using ELISA. Statistical analysis was done by SPSS using ANOVA with post-hoc study. Results Secretome alone increased tube formation by 42.3 ± 8.7% compared to control (p<0.01). The addition of dapagliflozin further enhanced angiogenesis to 78.5 ± 10.2% under normoxia (p<0.01). Under hypoxic conditions, the combined therapy has the highest effect, with a 96.1 ± 12.4% increase (p<0.001). eNOS expression was significantly upregulated, showing a 1.9-fold rise in normoxia and 2.4-fold rise in hypoxia (p<0.01), while VWF levels remained unchanged (p=0.41). Hypoxic preconditioning markedly amplified angiogenic responses with nearly double that of control and consistently superior to all normoxic groups. Conclusion Hypoxic preconditioning is a critical determinant that optimizes the pro-angiogenic efficacy of this novel hUCB-MSC secretome-based combination therapy. This strategy provides a promising novel regenerative treatment option for stable CAD patients.Figure 1.Tube assay analysis of angiogenesis development in the hypoxia-preconditioned group.
Reference Key
openalex_W7220381031 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors R E Intan, Y Azmi, P M H Putri, A Trissatharra, H O Hermawan, T T E Lusida, Y H Oktaviono, B B Dharmadjati
Are you one of these authors? Claim your profile
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag119.006
URL
https://doi.org/10.1093/eurheartjsupp/suag119.006
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.